LONGEVERON LLC has a total of 27 patent applications. It decreased the IP activity by 28.0%. Its first patent ever was published in 2017. It filed its patents most often in Canada, EPO (European Patent Office) and Israel. Its main competitors in its focus markets pharmaceuticals, measurement and biotechnology are KANISA PHARMACEUTICALS INC, ALPHAPTOSE GMBH and ALPHARMA PHARMACEUTICALS LLC.
# | Country | Total Patents | |
---|---|---|---|
#1 | Canada | 3 | |
#2 | EPO (European Patent Office) | 3 | |
#3 | Israel | 3 | |
#4 | Republic of Korea | 3 | |
#5 | United States | 3 | |
#6 | Australia | 2 | |
#7 | China | 2 | |
#8 | Singapore | 2 | |
#9 | Taiwan | 2 | |
#10 | WIPO (World Intellectual Property Organization) | 2 | |
#11 | South Africa | 2 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Measurement | |
#3 | Biotechnology |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Medical preparations | |
#3 | Analysing materials | |
#4 | Microorganisms |
# | Name | Total Patents |
---|---|---|
#1 | Hare Joshua M | 22 |
#2 | Landin Ana Marie | 14 |
#3 | Difede Darcy L | 8 |
#4 | Ana Marie Landin | 2 |
#5 | Joshua M Hare | 2 |
Publication | Filing date | Title |
---|---|---|
WO2018236680A1 | Treatment of sexual dysfunction and improvement in sexual quality of life | |
KR20190084091A | Use of human mesenchymal stem cells to elicit cellular and humoral immunity | |
KR20180105705A | Mesenchymal stem cells as vaccine adjuvants and methods for their use |